论文部分内容阅读
目的建立造血干细胞诱导门脉耐受模型，并探讨其机制．方法门静脉或尾静脉注射ＰＫＨ一２６标记或未标记的全异基因造血细胞，利用流式细胞技术等观察免疫耐受的建立与否、供体细胞表型、宿主肝胜十造血灶的形成及其来源等指标．结果当同基因或异基因全骨髓细胞（ＢＭＣ）或造血干细胞（ＨＳＣ）富含部分经尾静脉或门静脉注射后，均首先在肝脏聚集，且聚集在肝脏的细胞为ＷＧＡ＋的ＨＳＣ．在异基因ＢＭＣ门脉注射后ｄ１０，可在宿主肝脏中发现供体ＨＳＣ来源的造血灶形成，而尾静脉注射异基因ＢＭＣ组则几乎见不到造血灶的形成．进一步研究表明，以未标记Ｂ６ＢＭＣ通过足静脉免疫ＢＡＬＢ／Ｃ小鼠，则随后移植的Ｂ６脾细胞被迅速排斥，而通过门静脉免疫，则可使随后移植的Ｂ６脾细胞长期存活．结论门脉注射异基因ＢＭＣ可诱导供体特异性耐受；在耐受诱导和维持中起关键作用的细胞为聚集在肝脏中的ＨＳＣ。
Objective To establish a hematopoietic stem cell-induced portal vein tolerance model and to explore its mechanism. Methods The portal vein or tail vein was injected with PKH-26 labeled or unlabeled allogeneic hematopoietic cells. Flow cytometry was used to observe the establishment of immune tolerance, donor cell phenotype, Its source and other indicators. Results All of the syngeneic or allogenic bone marrow cells (BMCs) or hematopoietic stem cells (HSCs) were partially accumulated in the liver via tail vein or portal vein injection. The cells aggregated in the liver were WGA + HSCs. Donor HSC-derived hematopoietic foci were found in the donor liver at 10 days after allogeneic BMC portal injection, whereas almost no formation of hematopoietic foci was found in the tail vein-injected allogeneic BMC group. Further studies showed that immunization of BALB / C mice with unlabeled B6BMC through the foot vein resulted in the rapid rejection of the B6 splenocytes that were subsequently transplanted, whereas subsequent transplants of B6 splenocytes survived after portal vein immunization. Conclusion Intravenous injection of allogeneic BMC induces donor-specific tolerance. HSC, which plays a key role in tolerance induction and maintenance, is aggregated in the liver.